AU Patent

AU2019375972A1 — Use of tivozanib to treat subjects with refractory cancer

Assigned to Aveo Pharmaceuticals Inc · Expires 2021-05-27 · 5y expired

What this patent protects

Disclosed is a method of treating cancer,

USPTO Abstract

Disclosed is a method of treating cancer,

Drugs covered by this patent

tivozanib-hydrochloride (TIVOZANIB HYDROCHLORIDE)

Patent Metadata

Patent number: AU2019375972A1
Jurisdiction: AU
Classification: —
Expires: 2021-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Aveo Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.